News | November 14, 2023
Biocon Biologics receives MHRA, UK Approval for Biosimilar Aflibercept ‘Yesafili’
Yesafili, received marketing authorization approval from the European Commission for the European Union
Yesafili, received marketing authorization approval from the European Commission for the European Union
The newly developed adhesive is available in two different grades. Loctite WT 3001 and Loctite WT 3003 h
In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
India is following a holistic and inclusive approach in alignment with the vison of Universal Health Coverage and the resolute commitment to ‘leave no one behind
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
The companies plan to start a pivotal Phase 3 trial in the coming months
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Subscribe To Our Newsletter & Stay Updated
